TQB3201, developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., represents a novel approach in the treatment of advanced prostate cancer, particularly in patients who have developed resistance to existing anti-androgen therapies. The drug's mechanism as a PROTAC (proteolysis-targeting chimera) allows it to target and degrade both wild-type and mutant forms of the androgen receptor, addressing a significant unmet need in the metastatic castration-resistant prostate cancer (mCRPC) market. Given the increasing prevalence of prostate cancer and the limitations of current therapies, TQB3201 could capture a substantial market share if it demonstrates favorable safety and efficacy profiles. Competitive analysis indicates that while there are several therapies available, TQB3201's unique mechanism may provide a differentiated therapeutic option. Diligence should focus on the trial's enrollment timelines and the competitive landscape as it progresses through clinical phases.